Squarepoint’s Ginkgo Bioworks DNA Stock Holding History

Squarepoint’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$155K	Sell	15,689 -39,241	-71%	-$328K	﹤0.01%	4123
2026 Q1	$337K	Sell	54,930 -141,890	-72%	-$1.18M	﹤0.01%	3620
2025 Q4	$1.64M	Buy	+196,820	New	+$2.12M	﹤0.01%	2193
2025 Q2	–	Sell	-117,679	Closed	-$671K	–	4608
2025 Q1	$671K	Buy	117,679 +75,189	+177%	+$766K	﹤0.01%	3022
2024 Q4	$417K	Sell	42,490 -60,696	-59%	-$520K	﹤0.01%	3894
2024 Q3	$841K	Buy	103,186 +94,446	+1,081%	+$946K	﹤0.01%	2734
2024 Q2	$117K	Sell	8,740 -9,857	-53%	-$294K	﹤0.01%	3767
2024 Q1	$863K	Buy	18,597 +18,217	+4,794%	+$943K	﹤0.01%	2697
2023 Q4	$25.7K	Buy	+380	New	+$23.3K	﹤0.01%	3902
2023 Q2	–	Sell	-36,377	Closed	-$1.94M	–	3651
2023 Q1	$1.94M	Buy	+36,377	New	+$2.31M	0.01%	1433
2022 Q3	–	Sell	-2,297	Closed	-$219K	–	3082
2022 Q2	$219K	Buy	2,297 +696	+43%	+$84.9K	﹤0.01%	2429
2022 Q1	$258K	Buy	+1,601	New	+$312K	﹤0.01%	2359

Other funds holding DNA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACG

Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JMFC

J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

Squarepoint's DNA Position: Q2 2026 in Review

Squarepoint reduced its Ginkgo Bioworks (DNA) stake by 71% in Q2 2026, selling an estimated $328K and leaving 15,689 shares worth $155K. The position accounts for ﹤0.01% of the portfolio, ranked #4123.

Squarepoint first reported a position in DNA in Q1 2022 and has held it in 12 quarters since. The position peaked at $1.94M in Q1 2023. 184 funds tracked by Wall St. Rank hold DNA as of Q2 2026.

Squarepoint held 15,689 shares of Ginkgo Bioworks worth $155K as of Q2 2026.
Squarepoint sold 39,241 Ginkgo Bioworks shares in Q2 2026, an estimated $328K.
Ginkgo Bioworks made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #4123 holding.
Squarepoint first reported a position in Ginkgo Bioworks in Q1 2022 and has held it in 12 quarters since.
Squarepoint's Ginkgo Bioworks position peaked at $1.94M in Q1 2023.
184 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.